CRDF · CIK 0001213037 · operating
Cardiff Oncology is a clinical-stage biotechnology company developing targeted cancer therapies for oncology indications. The company's lead candidate, Onvansertib, is an oral, selective polo-like kinase 1 inhibitor designed to treat RAS-mutated metastatic colorectal cancer. The company is advancing Onvansertib through multiple clinical programs, including a Phase 2 randomized trial evaluating the drug in combination with standard chemotherapy regimens in patients with metastatic colorectal cancer harboring KRAS or NRAS mutations, as well as investigator-initiated trials in pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia.
The company operates as a pre-revenue clinical-stage entity focused on advancing its pipeline candidates through clinical development. Cardiff Oncology maintains a lean operational footprint with approximately 30 full-time employees and is headquartered in San Diego, California. The company was incorporated in Delaware and changed its name to Cardiff Oncology in 2012, following its original founding in 1999 as Trovagene, Inc. Its securities are listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.69 | $-0.69 | +27.4% | |
| 2024 | $-0.95 | $-0.95 | -2.2% | |
| 2023 | $-0.93 | $-0.93 | -4.5% | |
| 2022 | $-0.89 | $-0.89 | -21.9% | |
| 2021 | $-0.73 | $-0.73 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | $-8.26 | $-8.26 | -13666.7% | |
| 2017 | $-0.06 | $-0.06 | +82.4% | |
| 2016 | $-0.34 | $-0.28 | -30.8% | |
| 2015 | $-0.26 | $-0.25 | -4.0% | |
| 2014 | $-0.25 | $-0.25 | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-24 | 0001193125-26-067464 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0000950170-25-028992 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001628280-24-007948 | SEC ↗ |
| 2022-12-31 | 2023-03-02 | 0001628280-23-006037 | SEC ↗ |
| 2021-12-31 | 2022-02-24 | 0001628280-22-003808 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001628280-21-003277 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001628280-20-002424 | SEC ↗ |
| 2018-12-31 | 2019-03-06 | 0001628280-19-002546 | SEC ↗ |
| 2017-12-31 | 2018-02-26 | 0001628280-18-002226 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001628280-17-002601 | SEC ↗ |
| 2015-12-31 | 2016-03-10 | 0001628280-16-012562 | SEC ↗ |
| 2014-12-31 | 2015-03-12 | 0001104659-15-019213 | SEC ↗ |
| 2013-12-31 | 2014-03-17 | 0001104659-14-020261 | SEC ↗ |
| 2012-12-31 | 2013-04-01 | 0001104659-13-026211 | SEC ↗ |
| 2011-12-31 | 2012-03-30 | 0001104659-12-022906 | SEC ↗ |